FindTrial
Sign In

Safety and Efficacy of G-CSF 'filgrastim BS' administration in the peripheral blood stem cell (PBSC) mobilization

Safety and Efficacy of G-CSF 'filgrastim BS' administration in the peripheral blood stem cell (PBSC) mobilization - Safety and Efficacy of filgrastim BS in the PBSC mobilization

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015132
Enrollment
20
Registered
2014-09-11
Start date
2013-12-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Related donors for allogeneic PBSC transplantation

Interventions

Subcutaneous administration of filgrastim BS 300mcg twice daily on days 1-4 and one dose on day 5. Complete blood count is carried out on days 1-5. PBSCs are harvested on days 4 and 5.

Sponsors

Div. Hematology and Div. Transfusion Medicine, Kanazawa University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Give informed consent for the PBSC mobilization by G-CSF administration. 2. Enroll in the accident insurance for the PBSC mobilization. 3. Give informed consent for the current study, approved by the institutional ethics comittee.

Exclusion criteria

Exclusion criteria: In case the attending physician judge the candidate not suitable for this study.

Design outcomes

Primary

MeasureTime frame
1. Adverse events during the PBSC mobilization 2. Efficacy of the PBSC mobilization—

Countries

Japan

Contacts

Public ContactKUBOTA, Chizuru

Kanazawa University Hospital Hematology

ckubota@staff.kanazawa-u.ac.jp076-265-2275

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026